Progevera 10 mg® Versus Orgalutran® in Ovarian Stimulation Cycles of Oocyte Donors

Fundació Privada Eugin232 enrolled

Overview

Evaluation of efficacy and safety of medroxiprogesterone acetate (Progevera 10 mg®) versus GnRh antagonist (Orgalutran®) in ovarian stimulation cycles of oocyte donors

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

OTHER

Masking

NONE

Enrollment

232

Conditions

Infertility

Interventions

ProgeveraDRUG

OrgalutranDRUG

Eligibility

Sex: FEMALEMin age: 18 YearsMax age: 35 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Oocyte donors included in the oocyte donation program of Clinica EUGIN. * 1st oocyte donation cycle at Clínica EUGIN. Exclusion Criteria: * Polycistic Ovarian syndrome (PCOs). * Estradiol levels on day 2 of menstrual cycle \>70 pg/ml. * Hormone treatments up to 3 months before the oocyte donation cycle. * Medical contraindication to the treatments used in the study

Locations (1)

Clinica Eugin

Barcelona, Spain

Outcomes

Primary Outcomes

donor ovarian response

Time frame: 1 month

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.